|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.73 - 14.99|
|52 Week Range||14.30 - 44.42|
|PE Ratio (TTM)||-2.44|
|Forward Dividend & Yield||1.10 (7.40%)|
|1y Target Est||N/A|
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that new data on its multiple sclerosis (MS) program, including COPAXONE® (glatiramer acetate injection), a product for relapsing forms of MS, and laquinimod, an investigational MS therapy, will be highlighted in 11 presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in Paris, October 25-28, 2017. “New data from Teva’s MS program further contributes to the scientific understanding of treating a complex disease like MS,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva.
Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
Shares of several large generic drugmakers fell in Wednesday midday trade. Mylan NV shares dropped 2.7%, Teva Pharmaceutical Industries Ltd. shares dropped 2.1% , Taro Pharmaceutical Industries Ltd. shares ...
Kare Schultz will start his new post as chief executive of Israel's Teva Pharmaceutical Industries by the end of October, the Calcalist financial newspaper reported on Tuesday. A Teva spokesman, asked about the Israeli news report, said the company does not comment on market rumours. Teva poached Schultz from Denmark's Lundbeck in September, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. TEVA Chief Scientific Officer Michael Hayden commented, "The BLA submission for fremanezumab marks a very important milestone for the migraine community [...] There have been few therapeutic innovations for migraine patients in over 25 years. If approved, fremanezumab will be among the first to enter the market in a new class of drugs for the preventive treatment of migraine.
BDSI further said that additional terms of the settlement agreement are confidential and that the agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. A Teva spokeswoman confirmed the settlement agreement and launch date.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.